Literature DB >> 3712094

Immunoreactivity assay for labeled anti-melanoma monoclonal antibodies.

P L Beaumier, D Neuzil, H M Yang, E A Noll, R Kishore, J F Eary, K A Krohn, W B Nelp, K E Hellström, I Hellström.   

Abstract

A convenient, rapid, and reproducible assay was developed to evaluate the immunoreactivity of radiolabeled monoclonal antibodies against three different human melanoma-associated antigens, p97, a proteoglycan and a GD3 ganglioside. A cloned melanoma cell line (M 2669 CL 13) was selected as the target and, when fixed with paraformaldehyde, showed binding as good as or better than that obtained with live cells for the three antigens. Fixed cells retained good binding properties stored at 4 degrees C for over 6 mo. This assay has general applicability to other antigen-antibody systems for testing chemically modified monoclonal antibodies or fragments during the development of a radiopharmaceutical or as a routine quality control measure for clinical agents.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3712094

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  4 in total

1.  Monoclonal antibody L6-daunomycin conjugates constructed to release free drug at the lower pH of tumor tissue.

Authors:  E Lavie; D L Hirschberg; G Schreiber; K Thor; L Hill; I Hellstrom; K E Hellstrom
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

2.  Comparative tumour localization properties of radiolabelled monoclonal antibody preparations of defined immunoreactivities.

Authors:  M V Pimm; R W Baldwin
Journal:  Eur J Nucl Med       Date:  1987

3.  Antitumor effects of L6, an IgG2a antibody that reacts with most human carcinomas.

Authors:  I Hellström; P L Beaumier; K E Hellström
Journal:  Proc Natl Acad Sci U S A       Date:  1986-09       Impact factor: 11.205

4.  Optimization of in vivo tumor targeting in SCID mice with divalent forms of 741F8 anti-c-erbB-2 single-chain Fv: effects of dose escalation and repeated i.v. administration.

Authors:  G P Adams; J E McCartney; E J Wolf; J Eisenberg; M S Tai; J S Huston; W F Stafford; M A Bookman; L L Houston; L M Weiner
Journal:  Cancer Immunol Immunother       Date:  1995-05       Impact factor: 6.968

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.